PROKIDNEY CORP.

ProKidney Corp. (Nasdaq: PROK) is a clinical-stage biopharmaceutical company developing renal autologous cell therapy for patients with chronic kidney disease and type 2 diabetes. The company became publicly traded through its de-SPAC merger with SCS Capital Acquisition Corp., a blank-check vehicle sponsored by SCS Capital Management that completed its initial public offering in 2021. The business combination closed in 2023, bringing ProKidney into the public markets under the healthcare and biotechnology sector. The company submitted an 8-K filing with the Securities and Exchange Commission on August 10, 2026. For complete filing history, SPAC deal analytics, and real-time data on PROK, sign up for full access at SpacDesk.